CANNABIS IN THE MANAGEMENT OF PATHOLOGIES- LITERATURE REVIEW

Authors

  • Rafael Maciel de Paulo
  • Breno Silva de Abreu

Keywords:

Cannabis, cannabinoids, cannabidiol, marijuana

Abstract

The medicinal decline of Cannabis came with the appearance of other substances and the difficulty of isolating its active principle. The Israeli professor, Raphael Mechoulan, was able to identify and isolate the main components of this plant, allowing a greater knowledge about a Cannabis. It has about four hundred substances. Among these substances, delta-9-tetrahydrocannabinol and cannabidiol, one responsible for psychoactive effects and the other for not being psychoactive, were the most interesting ones. In studies, it was possible to perceive that there are different species of Cannabis, and Cannabis sativa is characterized by a high THC content, Cannabis indica having a low THC content and Cannabis ruderalis that has no psychoactive substance. Another finding that drew much attention was that of cannabinoid receptors. Being CB1, which has great concentration in the brain and are responsible for most of the psychoactive effects, CB2, which are found in the immune system, and finally CB3 which is the way they call the other non-CB1 / CB2 cannabinoid receptors. With the advancement of medicine and all these discoveries it was possible to carry out studies with Cannabis and to prove that it has pharmacological effects. Today, this plant is used in the treatment of multiple sclerosis, Parkinson's disease, Alzheimer's, epilepsy, AIDS, glaucoma, schizophrenia, anxiety, weight reduction and insomnia.

References

Matos RLA, Spinola LA, Barboza LL, Garcia DR, França TC, Affonso RSO. Uso do Canabidiol no Tratamento da Epilepsia. Revista Virtual de Química. 2017; Volume 9(2): 2-13.

Crippa JAS, Zuardi AW, Hallak JEC. Uso terapêutico dos canabinoides em psiquiatria. Revista Brasileira de Psiquiatria. 2010; Volume 32: 1-3.

Coutinho MPL, Araújo LF, Gonties B. Uso da maconha e suas representações sociais: estudo comparativo entre universitários. Psicologia em Estudo. 2004; Volume 9(3): 2-3.

Honório KM, Arroio A, Silva ABF. Aspectos terapêuticos de compostos da planta Cannabis sativa. Química Nova. 2006; Volume 29(2) : 318-319.

Iglésias FA. Sobre o vício da diamba.

Barreto LAAS. A maconha (Cannabis sativa) e seu valor terapêutico. Monografia [Trabalho de conclusão de curso de Ciências Biológicas]. Brasília : Centro Universitário de Brasília - UNICEUB; 2002.

Oliveira KLB, Lima TPS. Cannabis sativa: potencial terapêutico. Monografia [Trabalho de conclusão de curso de Biomedicina]. Porto Velho : Faculdade São Lucas; 2016.

Pedrazzi JFC, Pereira ACC, Gomes FV, Del Bel E. Perfil antipsicótico do canabidiol. Revista da Faculdade de Medicina de Ribeirão Preto. 2014; Volume 47(2): 115-7.

Schier ARM, Ribeiro NPO, Silva ACO, Hallak JEC, Crippa JAS, Nardi AE et al. Canabidiol, um componente da Cannabis sativa, como um ansiolítico. Revista Brasileira de Psiquiatria. 2012; Volume 34: 4-5.

Ribeiro JAC. A Cannabis e suas aplicações terapêuticas. Dissertação [Mestrado em Ciências Farmacêuticas]. Porto: Universidade Fernando Pessoa; 2014.

Costa JLGP, Maia LO, Orlandi-Mattos P, Villares JC, Esteves MAF. Neurobiologia da Cannabis: do sistema endocanabinoide aos transtornos por uso da Cannabis. Jornal Brasileiro de Psiquiatia. 2011; Volume 60(2) : 113-114.

Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale Farmacologia. 8° edição. São Paulo: Elsevier; 2016.

Maconha sintética causa “zumbi” nos usuários. Revista VEJA, São Paulo, 19 de Dezembro de 2016.

Published

2018-03-26

How to Cite

Paulo, R. M. de, & Abreu, B. S. de. (2018). CANNABIS IN THE MANAGEMENT OF PATHOLOGIES- LITERATURE REVIEW . Revista De Divulgação Científica Sena Aires, 4(2), 136–145. Retrieved from https://rdcsa.emnuvens.com.br/revista/article/view/796

Issue

Section

Literature Review